Literature DB >> 31850984

Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Propensity Score-matched Study.

Sanne Lof1,2, Maarten Korrel3, Jony van Hilst3, Alma L Moekotte1, Claudio Bassi4, Giovanni Butturini5, Ugo Boggi6, Safi Dokmak7, Bjørn Edwin8, Massimo Falconi9, David Fuks10, Matteo de Pastena4, Alessandro Zerbi11, Marc G Besselink3, Mohammed Abu Hilal1,2.   

Abstract

OBJECTIVE: The aim of this study was to investigate the impact of conversion during minimally invasive distal pancreatectomy (MIDP) for pancreatic ductal adenocarcinoma (PDAC) on outcome by a propensity-matched comparison with open distal pancreatectomy (ODP).
BACKGROUND: MIDP is associated with faster recovery as compared with ODP. The high conversion rate (15%-25%) in patients with PDAC, however, is worrisome and may negatively influence outcome.
METHODS: A post hoc analysis of a retrospective cohort including distal pancreatectomies for PDAC from 34 centers in 11 countries. Patients requiring conversion were matched, using propensity scores, to ODP procedures (1:2 ratio). Indications for conversion were classified as elective conversions (eg, vascular involvement) or emergency conversions (eg, bleeding).
RESULTS: Among 1212 distal pancreatectomies for PDAC, 345 patients underwent MIDP, with 68 (19.7%) conversions, mostly elective (n = 46, 67.6%). Vascular resection (other than splenic vessels) was required in 19.1% of the converted procedures. After matching (61 MIDP-converted vs 122 ODP), conversion did not affect R-status, recurrence of cancer, nor overall survival. However, emergency conversion was associated with increased overall morbidity (61.9% vs 31.1%, P= 0.007) and a trend to worse oncological outcome compared with ODP. Elective conversion was associated with comparable overall morbidity.
CONCLUSIONS: Elective conversion in MIDP for PDAC was associated with comparable short-term and oncological outcomes in comparison with ODP. However, emergency conversions were associated with worse both short- and long-term outcomes, and should be prevented by careful patient selection, awareness of surgeons' learning curve, and consideration of early conversion when unexpected intraoperative findings are encountered.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 31850984     DOI: 10.1097/SLA.0000000000003717

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   13.787


  4 in total

1.  Risk factors and outcomes of conversion in minimally invasive distal pancreatectomy: a systematic review.

Authors:  A Balduzzi; N van der Heijde; A Alseidi; S Dokmak; M L Kendrick; P M Polanco; D E Sandford; S V Shrikhande; C M Vollmer; S E Wang; H J Zeh; M Abu Hilal; H J Asbun; M G Besselink
Journal:  Langenbecks Arch Surg       Date:  2020-12-10       Impact factor: 3.445

2.  The Usefulness of a Preoperative Nomogram for Predicting the Probability of Conversion from Laparoscopic to Open Distal Pancreatectomy: A Single-Center Experience.

Authors:  Riccardo Casadei; Claudio Ricci; Carlo Ingaldi; Laura Alberici; Maria Chiara Vaccaro; Elisa Galasso; Francesco Minni
Journal:  World J Surg       Date:  2020-10-15       Impact factor: 3.352

Review 3.  What Is the Current Role and What Are the Prospects of the Robotic Approach in Liver Surgery?

Authors:  Emre Bozkurt; Jasper P Sijberden; Mohammed Abu Hilal
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

4.  The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol.

Authors:  Menghua Dai; Hanyu Zhang; Yinmo Yang; Dianrong Xiu; Bing Peng; Bei Sun; Feng Cao; Zheng Wu; Lei Wang; Chunhui Yuan; Hua Chen; Zheng Wang; Xiaodong Tian; Hangyan Wang; Wenjing Liu; Jianwei Xu; Qiaofei Liu; Yupei Zhao
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.